Updated BOND-003 data support durability of cretostimogene grenadenorepvec in NMIBC

高风险非muscle invasvie bladder cancer（NMIBC）患者中的BCG无响应性治疗，cretostimogene grenadenorepvec的耐用性和安全性均有实证。根据BOND-003试验的最新数据，12个月内的完全响应（CR）患者中，有90%仍在CR状态于24个月；24个月的CR率为41.8%。该药物的安全性良好，无grade 3或更高治疗相关不良事件（TRAEs）的报告。该药物的耐用性和安全性使其有望成为bladder cancer患者的突破性治疗选择。

来源: urologytimes

原文链接：原文

参考文献

1. CG Oncology continues to demonstrate best-in-disease durability and tolerability in BOND-003 cohort C; additional 12 patients in complete response at 24 months. News release. CG Oncology, Inc. September 5, 2025. Accessed September 5, 2025. https://www.globenewswire.com/news-release/2025/09/05/3145193/0/en/CG-Oncology-Continues-to-Demonstrate-Best-in-Disease-Durability-and-Tolerability-in-BOND-003-Cohort-C-Additional-12-Patients-in-Complete-Response-at-24-Months.html
2. Tyson M, Uchio EM, Nam JK, et al. Encore durability results from BOND-003 cohort C- phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Presented at: New England Section of the American Urological Association 94 Annual Meeting. September 4-6, 2025. Boston Massachusetts. Abstract 58